Generics BulletinAs the name of the event suggested, Teva’s 29 May Innovation & Strategy Day presentation focused chiefly on plans to expand its branded medicines business, including a roadmap to achieve $2.5bn in
Generics BulletinTeva has filled a gap in its non-US oncology portfolio after inking a license and supply agreement with Prestige BioPharma to commercialize the Singaporean firm’s Tuznue (trastuzumab) biosimilar to Ro
ScripBiopharmaceutical companies raised just $13.1bn during the first quarter of 2025 – less than half of the $30.1bn raised in Q1 of 2024, the latest Financing Quarterly Statistics report from Biomedtra
ScripThe capital markets continue to shy away from relatively risky investments, such as drug development, providing new funding for a limited number of companies. That means a lot of biopharmaceutical fir